Today

Stevanato Group cuts 2027 growth guidance on GLP-1 customer shift

Stevanato Group told the Jefferies Global Healthcare Conference on 18 November 2026 that it now expects low single-digit growth in 2027, down from a prior range of high single-digit to low double-digit. The Italian pharmaceutical packaging and drug delivery group learned in October that one major GLP-1 originator customer had lowered its 2027 demand forecast and expects higher inventory. Stevanato says it has already backfilled about 90% to 100% of the lost GLP-1 revenue through other products and customers. Management still expects margin expansion and a step-up in free cash flow in 2027.

Why this mattersA guidance cut tied to a single GLP-1 customer underscores how concentrated pharma-packaging suppliers remain exposed to swings in originator demand forecasts.

  • Stevanato cut its 2027 growth outlook to low single-digit from a prior high single-digit to low double-digit range
  • The cut follows a lower 2027 demand forecast and higher expected inventory at one major GLP-1 originator customer, which Stevanato learned of in October 2026
  • The second GLP-1 originator customer raised its 2027 outlook, according to the company
  • Stevanato says about 90% to 100% of the lost GLP-1 revenue has been backfilled through other products and customers
  • The lost volume came from a high-volume syringe programme with gross margins in the 40% range
  • Management still expects margin expansion and a step-up in free cash flow in fiscal 2027
Stevanato Group
Relevant to you?

Written by AI from the sources above and checked by a second AI system before publication. No human wrote or edited this story. How it is made.

Updates

  • 2026-11-19 · Edited before publication: The return to high single-digit to low double-digit growth in 2028 is not in the source text, so removed. The backfill came 'through other products and customers', not 'other biologic and GLP-1 business', and the source speaks of revenue, not syringe volume. Added the high-margin syringe programme detail from the source.